<DOC>
	<DOCNO>NCT02519816</DOCNO>
	<brief_summary>Phase II multicenter , Canadian study - open 25 subject . Study open subject steroid-refractory dependent chronic graft v host disease . Series 6 aphereses 28 re-infusions 24 week . Primary endpoint FFS 24 week . Primary objective measure efficacy CARE ( Continuous Alloreactive T-Cell depletion Regulatory T-cell Expansion )</brief_summary>
	<brief_title>Continuous Alloreactive T Cell Depletion Regulatory T Cell Expansion Treatment Steroid-refractory Dependent Chronic GVHD</brief_title>
	<detailed_description />
	<mesh_term>Immune System Diseases</mesh_term>
	<mesh_term>Plasma-lyte 148</mesh_term>
	<criteria>( Main ) 1 . Newly diagnose chronic GVHD define National Institutes Health ( NIH ) Consensus 24 week treatment systemic steroid . AND 2 . Chronic GVHD must refractory dependent standard therapy , define ( one follow ) : Progression prednisone 7 mg/kg/week 2 week , Stable disease â‰¥ 3.5 mg/kg/week prednisone 48 week , Inability taper prednisone 3.5 mg/kg/week . ( Main ) 1 . Persistent , recurrent lateonset acute GVHD , without sign chronic GVHD . OR 2 . Overlap GVHD syndrome uncontrolled feature previously diagnose acute GVHD . OR 3 . Treatment two systemic nonsteroidal immunosuppressant within 4 week prior enrollment . OR 4 . Time allogeneic transplantation &gt; 2 year . OR 5 . Lymphocyte count &lt; 0.2 x 109/L two last consecutive CBCs inclusion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>post stem cell transplantation</keyword>
	<keyword>Steroid refractory</keyword>
	<keyword>dependent chronic</keyword>
</DOC>